Kronos Bio Insider Clears Out Equity as Concentra Deal Closes
Rhea-AI Filing Summary
Form 4 snapshot: Kronos Bio (KRON) director Elena Ridloff reported the disposal of her remaining equity on 20 Jun 2025 following the closing of the company’s merger with Concentra Biosciences. She tendered 25,296 common shares, each exchanged for $0.57 in cash plus one contingent value right (CVR), matching the terms of the tender offer that closed on 18 Jun 2025. All of Ridloff’s outstanding stock options—covering 136,200 shares with strike prices between $0.95 and $24.18—were automatically cancelled because every exercise price exceeded the $0.57 cash component, so no additional consideration was received. After these transactions she holds zero shares or options, and Kronos Bio is now a wholly owned subsidiary of Concentra Biosciences.
Positive
- Merger consideration confirmed: Shareholders (including insiders) received $0.57 in cash plus a CVR for each Kronos Bio share, providing definitive liquidity.
Negative
- None.
Insights
TL;DR: Filing confirms director’s exit position; reflects merger completion, cash payout of $0.57 + CVR, no fresh valuation signal.
The Form 4 is largely administrative. It reiterates previously announced deal economics—$0.57 per share cash and a CVR—now applied to a single insider’s holdings. Option cancellation indicates strike prices above the cash consideration, implying those instruments were far out-of-the-money. Because the merger terms were public since 1 May 2025, today’s disclosure adds little incremental information and should not move the market. It does, however, confirm final settlement mechanics and that insiders no longer retain equity, eliminating potential overhang.
TL;DR: Director’s Form 4 finalizes equity disposition under merger; governance transition to new parent complete.
This filing shows clean termination of insider ownership concurrent with Kronos Bio becoming a private, wholly owned subsidiary of Concentra Biosciences. The automatic vest-and-cancel treatment of options follows standard M&A practice when strike prices exceed deal value, limiting windfalls and aligning payouts with shareholders. With no remaining insider stakes, legacy board influence over the public entity ceases, paving the way for parent-level governance. From a compliance perspective, the report meets Section 16 obligations and signals that Form 4/5 filing requirements will likely cease going forward.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 25,879 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 26,871 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 15,450 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 34,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 17,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 17,000 | $0.00 | -- |
| U | Common Stock | 25,296 | $0.57 | $14K |
Footnotes (1)
- Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
